Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient inhibitor of VEGFR1-3, FGFR1-3, and PDGFRalpha/β, useful in metastatic breast cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient inhibitor of VEGFR1-3, FGFR1-3, and PDGFRalpha/β, useful in metastatic breast cancer research. |
Targets&IC50 | FGFR2:82.5 nM, FGFR1:17.5 nM, VEGFR1:7 nM, VEGFR2:25 nM, VEGFR3:10 nM |
In vitro | Lucitanib dihydrochloride (E-3810 dihydrochloride) has potent inhibitory effects on VEGFR and FGFR autophosphorylation and can effectively inhibit VEGF- and bFGF-induced HUVEC proliferation with IC50 values of 40 and 50 nM, respectively. It can also inhibit CSF-1R with an IC50 value of 5 nM. [1] |
In vivo | Lucitanib dihydrochloride (E-3810 dihydrochloride) (20 mg/kg, oral, 7 days) treated mice, Lucitanib completely inhibited the bFGF-induced angiogenic response. Methods: Lucitanib dihydrochloride (15 mg/kg, oral, 30 days) was treated in mice bearing the MDA-MB-231 advanced breast cancer model, and tumor size was evaluated in vivo. Results: Lucitanib dihydrochloride effectively stabilized tumor growth. [3] |
Alias | E-3810 dihydrochloride, E3810 dihydrochloride, CO-3810 dihydrochloride, CO3810 dihydrochloride, AL3810 dihydrochloride, AL 3810 dihydrochloride |
Molecular Weight | 516.42 |
Formula | C26H27Cl2N3O4 |
Cas No. | 2108875-91-6 |
Smiles | O=C(C1=CC=CC2=CC(OC3=C4C=C(OC)C(OCC5(CC5)N)=CC4=NC=C3)=CC=C21)NC.Cl.Cl |
Storage | store at -20°C | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 16 mg/mL (30.98 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.